Avalo Therapeutics, Inc. (AVTX) income statement
AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$6.70−0.43 (-6.03%)
Close on Nov 18, 2026Market cap $359.32MP/E –Yield –
Avalo Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- -154844.1%
- Net margin
- -170055.9%
- Return on equity, FY2025
- -72.4%
Financial strength
- Current ratio
- 19.31
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 404.1%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.80
- Dividend yield
- –
See a number that looks wrong?